With twin platform technologies, Interprotein provides highly active modulators for protein-protein interaction (PPI) targets.

Our proprietary technology (INTENDD^®) is built upon a different conceptual foundation from MD-based docking simulation methods, generating highly active compounds with unique scaffolds.

On the other hand, our newly constructed libraries of helix-loop-helix peptide achieved a near 100% success rate in identifying strong binders with K_D values in low nanomolar range.

Change drug discovery

At Interprotein, we strive to revolutionize drug discovery with our expertise in analyzing and exploiting protein-protein interaction (PPI) interfaces to design and create PPI modulators. Targeting PPIs for therapeutic intervention with small molecules have long been postulated as plausible, but the number of authentic PPI inhibitors on the market is limited.

As the success of therapeutic antibodies shows, PPIs are proven targets especially for cell surface receptors and growing interests are being focused on PPI modulators in the increasingly difficult R&D environment in drug discovery due to less and less druggable targets after easy targets are already harvested. Protein-protein "interactomes" predict the number of putative PPIs in the range between 130,000 to 650,000. Therefore, we are actually seeing a sea of druggable targets in front of us. Yet, many of us are still struggling to exploit PPI interfaces for the development of PPI modulators.

We believe that we can change this situation with our twin proprietary technologies; INterprotein’s ENgine for new Drug Design, (INTENDD^®) , a structure-based drug discovery (SBDD) strategy for small molecules, and helix-loop-helix peptide, a conformationally-constrained peptide with a unique modality.

INTENDD^®

With INTENDD^®, we aim to develop and provide an in silico drug design platform specialized for producing small molecule PPI modulators, and extend this technology to establish an AI-based drug discovery program.

Helix-loop-helix peptide

Alternatively, we have developed extremely diverse libraries of helix-loop-helix peptides for phage-display screening. Phage-displayed random peptide screening enables us to achieve a near 100% success rate in identifying active peptides with high affinity and high specificity to PPI targets. In addition, we can easily modulate pharmacokinetic profiles via multiple approaches.

Our promise

Through collaborative R&D efforts, we will fully exploit our twin technologies for small molecules and peptides to identify highly active modulators against previously intractable PPI interfaces. We commit to turning current biologics (antibodies and soluble receptors)-based PPI inhibitions into more patient-friendly therapies with small molecule and/or peptide PPI modulators to change patients’ lives.